Medivir AB said Johnson & Johnson will terminate its license for hepatitis C treatment Olysio, also sold under the brand name Sovriad in Japan.
The Swedish company said Johnson & Johnson unit Janssen Pharmaceuticals Inc. made the decision after assessing the market demand for Olysio, or simeprevir.
The termination will become effective in June 2018, and Medivir will continue to receive royalties on any remaining sales of Olysio until then.
Medivir said it will seek potential commercialization partners for specific territories.
